CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [F]AlF-CD13-L1 PET/CT imaging.
[PURPOSE] Approximately 10% of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-negative, leading to blind spots in PSMA-based diagnosis.
- p-value p = 0.025
- p-value p = 0.015
APA
Tang W, Zhou M, et al. (2025). CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [F]AlF-CD13-L1 PET/CT imaging.. European journal of nuclear medicine and molecular imaging, 52(8), 2826-2840. https://doi.org/10.1007/s00259-025-07140-2
MLA
Tang W, et al.. "CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [F]AlF-CD13-L1 PET/CT imaging.." European journal of nuclear medicine and molecular imaging, vol. 52, no. 8, 2025, pp. 2826-2840.
PMID
39985618
Abstract
[PURPOSE] Approximately 10% of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-negative, leading to blind spots in PSMA-based diagnosis. This study aimed to identify a potential target for PSMA-negative PCa and preliminarily evaluate the feasibility of using radionuclide probe targeting the identified target for PCa diagnosis.
[METHODS] Quantitative protein analysis was performed on eight PSMA-negative PCa and eleven controls to identify a potential molecular target, followed by validation with an expanded cohort using immunohistochemistry. Sixteen participants underwent [F]AlF-CD13-L1 PET/CT scanning, with the PCa pathological tissues used as references to interpret the imaging results.
[RESULTS] Quantitative protein analysis revealed CD13 as the most significantly upregulated membrane protein in PSMA-negative PCa. Expanded validation results indicated that CD13 positivity rates were 92.9% (13/14), 82.7% (105/127), 91.7% (11/12), and 70% (14/20) in PSMA-negative PCa, PSMA-positive PCa, ductal adenocarcinoma of the prostate (DAC), and intraductal carcinoma of the prostate (IDC-P), respectively. In PCa participants, the median [F]AlF-CD13-L1 PET/CT maximum standardized uptake value (SUVmax) of tumors and tumor-to-muscle ratio were 4.3 (1.5-5.8) and 4.6 (1.7-6.1), respectively. The SUVmax value of the PCa lesions and the tumor-to-muscle ratio showed a positive correlation with the immunohistochemical score of CD13 of the PCa lesions (r = 0.6249, p = 0.025; r = 0.6714, p = 0.015, respectively), with CD13-positive tumors showing significant radiotracer accumulation.
[CONCLUSION] CD13 was a potential target for PSMA-negative PCa and also showed high positivity rates in PSMA-positive PCa, DAC, and IDC-P. [F]AlF-CD13-L1 selectively accumulated in CD13-positive PCa, enabling visualization. (Trial registration: ChiCTR2300077817. Registered November 21, 2023).
[METHODS] Quantitative protein analysis was performed on eight PSMA-negative PCa and eleven controls to identify a potential molecular target, followed by validation with an expanded cohort using immunohistochemistry. Sixteen participants underwent [F]AlF-CD13-L1 PET/CT scanning, with the PCa pathological tissues used as references to interpret the imaging results.
[RESULTS] Quantitative protein analysis revealed CD13 as the most significantly upregulated membrane protein in PSMA-negative PCa. Expanded validation results indicated that CD13 positivity rates were 92.9% (13/14), 82.7% (105/127), 91.7% (11/12), and 70% (14/20) in PSMA-negative PCa, PSMA-positive PCa, ductal adenocarcinoma of the prostate (DAC), and intraductal carcinoma of the prostate (IDC-P), respectively. In PCa participants, the median [F]AlF-CD13-L1 PET/CT maximum standardized uptake value (SUVmax) of tumors and tumor-to-muscle ratio were 4.3 (1.5-5.8) and 4.6 (1.7-6.1), respectively. The SUVmax value of the PCa lesions and the tumor-to-muscle ratio showed a positive correlation with the immunohistochemical score of CD13 of the PCa lesions (r = 0.6249, p = 0.025; r = 0.6714, p = 0.015, respectively), with CD13-positive tumors showing significant radiotracer accumulation.
[CONCLUSION] CD13 was a potential target for PSMA-negative PCa and also showed high positivity rates in PSMA-positive PCa, DAC, and IDC-P. [F]AlF-CD13-L1 selectively accumulated in CD13-positive PCa, enabling visualization. (Trial registration: ChiCTR2300077817. Registered November 21, 2023).
MeSH Terms
Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Aged; Middle Aged; Glutamate Carboxypeptidase II; CD13 Antigens; Antigens, Surface; Fluorine Radioisotopes; Theranostic Nanomedicine
같은 제1저자의 인용 많은 논문 (5)
- Prevalence and risk factors of lung nodules in a non-smoking Chinese population: a prospective study of low-dose computed tomography screening.
- Potential of small-molecule targeted drugs in combination with CAR-T cell therapy for hematologic lymphomas.
- Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer.
- Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
- Identification of RCN3-positive cancer-associated fibroblasts as novel drivers of colorectal cancer through a TGF-β pathway-based risk signature.